ReviewInvestigational new drugs2025

Assessing the risks and benefits of investigational new drugs in adult phase-I oncology trials in China, 2013-2021.

Zhizhou Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.